Response-adapted surgery after neoadjuvant immunochemotherapy in oral squamous cell carcinoma
RAS after NICT achieves oncologic outcomes equivalent to TS while significantly reducing treatment-related morbidity and improving functional recovery. These findings support RAS as a viable de-escalation strategy for OSCC, aligning with the goals of precision oncology. Prospective trials are needed to validate long-term efficacy and refine patient selection criteria.
Authors
- Lanwei Guo (ORCID: https://orcid.org/0000-0002-0822-2578)
- Junhui Yuan (ORCID: https://orcid.org/0000-0003-3312-8599)
- Qigen Fang (ORCID: https://orcid.org/0000-0002-7303-1030)
- Xu Zhang (ORCID: https://orcid.org/0000-0002-1959-1758)
- Tao Huang (ORCID: https://orcid.org/0000-0003-2607-8407)
Institutions
- Henan Cancer Hospital (CN)
Publication Details
- Journal
- Oral Oncology
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1016/j.oraloncology.2025.107769
- Citations
- 5
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 9.24